Pleiotropic effects of statins

  • John A. Farmer


The advent of statin therapy has revolutionized the ability of the clinician to manage patients at risk for the development of an ischemic event due to dyslipidemia. Large-scale clinical trials involving thousands of patients in both primary and secondary prevention have clearly demonstrated that statin therapy will reduce cardiovascular mortality across a broad spectrum of patient subgroups. Additionally, in adequately powered trials, total mortality has been successfully decreased by the use of statin therapy. However, the precise mechanism underlying the benefit of statin therapy has been controversial due to the multiplicity of potential benefits that statins have demonstrated in addition to pure lipid lowering. The causal theory of pharmacologic benefit reiterates the lipid hypothesis, which states that dyslipidemia is central to the process of atherosclerosis and the clinical benefit which accrues from statin therapy is a function of the degree of lipid lowering. The noncausal theory supports the premise that clinical benefits are related primarily to pleiotropic effects of statins (endothelial function, inflammation, coagulation and plaque vulnerability) as being the major modulators of clinical benefit. This review will focus on the potential beneficial effects of statin therapy on a number of the pleiotropic effects of statins and the potential role that these activities play in the reduction of risk for ischemic events.


Simvastatin Atorvastatin Pravastatin Tissue Factor Lovastatin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References and Recommended Reading

  1. 1.
    Kroon AA, Stalenhoef AF, Buikema H, et al.: The effect of cholesterol reduction on the endothelial function and progression of atherosclerosis in WHHL rabbits. Atherosclerosis 1993 Nov, 103(2): 221–230.PubMedCrossRefGoogle Scholar
  2. 2.
    Kaesemeyer WH, Caldwell RV, Huang J, Caldwell RW: Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol lowering action. J Am Coll Cardiol 1999 Jan, 31(1): 234–241.CrossRefGoogle Scholar
  3. 3.
    Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, et al.: Effect of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-I and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998 Jun 15, 101(12): 2711–2719.PubMedGoogle Scholar
  4. 4.
    Kano H, Hayashi T, Sumi D, et al.: An HMG CoA reductase inhibitor improved progression of atherosclerosis in the rabbit aorta without affecting serum lipid levels: possible relevance of upregulation of endothelial nitric oxide synthase mRNA. Biochem Biophsy Res Commun 1999 Jun 7, 259(2): 414–419.CrossRefGoogle Scholar
  5. 5.
    Alfon J, Guasch JF, Berrozpe M, Badimon L: Nitric oxide synthase-II (NOS-II) gene expression correlates with atherosclerotic intimal thickening. Preventive effects of HMG CoA reductase inhibitors. Atherosclerosis 1999 Aug, 145(2): 325–331.PubMedCrossRefGoogle Scholar
  6. 6.
    John S, Schlaich M, Langenfeld M, et al.: Increased bioavailability of nitric oxide after lipid lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study. Circulation 1998 Jul 21, 98(3): 211–216.PubMedGoogle Scholar
  7. 7.
    Schobel HP, Schmieder RE: Vasodilatory capacity of forearm resistance is augmented in hypercholesterolemic patients after treatment with fluvastatin. Angiology 1998 Sep, 49(9): 743–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Simons LA, Sullivan B, Simons J, Celermajer DS: The effects of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial endothelial function in patients with severe primary hypercholesterolemia. Atherosclerosis 1998 Mar, 137(1): 197–203.PubMedCrossRefGoogle Scholar
  9. 9.
    Dupuis J, Tardif JC, Cernacek E, Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (Reduction of Cholesterol in Ischemia and Function of the Endothelium) trial. Circulation 1999 Jun 29, 99(25): 3227–3233.PubMedGoogle Scholar
  10. 10.
    Ridker PM, Rifai N, Pheffer MA, et al.: Inflammation, pravastatin and the risk of coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998 Sep 1, 98(9): 839–844.PubMedGoogle Scholar
  11. 11.
    Ridker PM, Rifai N, Pheffer MA, et al.: Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999 Jul 20, 100(3): 230–235.PubMedGoogle Scholar
  12. 12.
    Kobashigawa JA, Katznelson S, Laks H, et al.: The effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995 Sep 7, 333(10): 621–627.PubMedCrossRefGoogle Scholar
  13. 13.
    Katznelson S, Huang XM, Chia D, et al.: The inhibitor effects of pravastatin on natural killer T-cell activity in vivo in cytotoxic T-lymphocyte activity in vitro. J Heart Lung Transplant 1998 Apr, 17(4): 335–340.PubMedGoogle Scholar
  14. 14.
    Bustos C, Hernandez-Presa MA, Ortego M, et al.: HMG-CoA reductase inhibition by atorvastatin reduces neo-intimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 1998 Dec, 32(7): 2057–2064.PubMedCrossRefGoogle Scholar
  15. 15.
    Kallen J, Welzenbach K, Ramage P, et al.: J Mol Biol 1999 Sep 10, 292(1): 1–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Osamah H, Mira R, Sorina S, et al.: Reduced platelet aggregation after fluvastain therapy is associated with altered platelet lipid composition and drug binding to the platelets. Br J Clin Pharmacol 1997 Jul, 44(1): 77–83.PubMedCrossRefGoogle Scholar
  17. 17.
    Aviram M, Hussein O, Rosenblat M, et al.: Interactions of platelets, macrophages and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG CoA reductase inhibitor therapy. J Cardiovasc Pharmacol 1998 Jan, 31(1): 39–45.PubMedCrossRefGoogle Scholar
  18. 18.
    Alfon J, Royo T, Garcia-Moll X, Badimon L,: Platelet deposition on eroded vessel walls at a stenotic shear rate is inhibited by lipid lowering therapy with atorvastatin. Arterioscler Thromb Vasc Biol 1999 Jul, 19(7): 1812–1817.PubMedGoogle Scholar
  19. 19.
    Lacoste L, Lam JY, Hung J, et al.: Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995 Dec 1, 92(11): 3172–3177.PubMedGoogle Scholar
  20. 20.
    Tremoli E, Camera M, Toschi D, Colli S: Tissue factor in atherosclerosis. Atherosclerosis 1999 Jun, 144(2): 273–283.PubMedCrossRefGoogle Scholar
  21. 21.
    Misumi K, Ogawa H, Yasue H, et al.: Comparison of tissue factor levels in unstable and stable angina pectoris. Am J Cardiol 1998 Jan 1:81(1): 22–26.PubMedCrossRefGoogle Scholar
  22. 22.
    Colli S, Eligini S, Lalli M, et al.: Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. Arterioscler Thromb Vasc Biol 1997 Feb, 17(2): 265–272.PubMedGoogle Scholar
  23. 23.
    Lorena M, Perolini S, Casazza S, et al.: Fluvastatin and tissue factor pathway inhibitor in type IIA and type IIB hyperlipidemia and in acute myocardial infarction. Thromb Res 1997 Aug, 84(4): 397–403.CrossRefGoogle Scholar
  24. 24.
    Ferro D, Basili S, Alessandri C, Mantovani B, Cordova C, Violi F. Simvastatin reduces monocyte tissue factor expression type IIA hypercholesterolemia. Lancet 1997 Oct 25, 350(9086): 1222.PubMedCrossRefGoogle Scholar
  25. 25.
    Lorena M, ibid.CrossRefGoogle Scholar
  26. 26.
    Kario K, Matsuo T, Hoshide S, et al.: Lipid-lowering therapy corrects endothelial cell dysfunction in a short time but does not affect hypercoagulable state even after long-term use in hyperlipidemic patients. Blood Coagul Fibrinolysis 1999 Jul, 10(5): 267–276.Google Scholar
  27. 27.
    Szczeklik A, Musial J, Undas A, et al.: Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. J Am Coll Cardiol 1999 Apr, 33(5): 1286–1293.PubMedCrossRefGoogle Scholar
  28. 28.
    Dangas G, Smith DA, Badimon JJ, et al.: Gender differences in blood thrombogenicity in hyperlipidemic patients in response to pravastatin. Am J Cardiol 1999 Sep 15, 84(6): 639–643.PubMedCrossRefGoogle Scholar
  29. 29.
    Gottsater A, Anwaar I, Lind E, et al.: Increasing plasma fibrinogen, but unchanged levels of intraplatelet cyclic nucleotide, plasma endothelin-I, factor VII and neopterin during cholesterol lowering with fluvastatin. Blood Coagul Fibrinolysis 1999 Apr, 10(3): 133–140.PubMedGoogle Scholar
  30. 30.
    Marais AD, Firth JC, Bateman ME, et al.: Atorvastatin: an effective lipid modifying agent in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1997 Aug, 17(8): 1527–1531.PubMedGoogle Scholar
  31. 31.
    Black DM: Statins and fibrinogen. Lancet 1998 May: 351(9113): 1430.PubMedCrossRefGoogle Scholar
  32. 32.
    Wada H, Mori Y, Kaneko T, et al.: Hypercoagulable state in patients with hypercholesterolemia: effects of pravastatin. Clin Ther 1992 Nov-Dec, 14(6): 829–834.PubMedGoogle Scholar
  33. 33.
    Mitropoulos KA, Armitage JM, Collins R, et al.: Randomized, placebo-controlled study of the effects of simvastatin on hemostatic variables, lipoproteins, and pre-fatty acids. The Oxford Cholesterol Study Group. Eur Heart J 1997 Feb, 18(2): 235–241.PubMedGoogle Scholar
  34. 34.
    Tan KC, Janus ED, Lam KS. Effects of fluvastatin on prothrombotic and fibrinolytic factors in type II diabetes. Am J Cardiol 1999 Oct 15, 84(8): 934–937, A7.PubMedCrossRefGoogle Scholar
  35. 35.
    Vogel RA: Cholesterol lowering and endothelial function. Am J Med 1999 Nov, 107(5): 479–487.PubMedCrossRefGoogle Scholar
  36. 36.
    Hackman A, Abe Y, Insull W, et al.: Effects of soluble adhesion cell molecules in patients with dyslipidemia. Circulation 1996 Apr 1, 93(7): 1334–1338.PubMedGoogle Scholar
  37. 37.
    Kimur A, Kuros C, Russell J, Granger DN: Effects of fluvastatin on leukocyte endothelial cell adhesion in hypercholesterolemic rats. Arterioscler Thromb Vasc Biol 1997 Aug, 17(8): 1521–1526.Google Scholar
  38. 38.
    Niwa S, Totsuka T, Hayashi S: Inhibitory effect of fluvastatin and HMG CoA reductase inhibitor on the expression of adhesion molecules on human monocyte cell life. Int J Immunopharmacol 1996 Nov, 18(11): 669–675.PubMedCrossRefGoogle Scholar
  39. 39.
    Dunzendorfer S, Rophbucher D, Schratzberger T, et al.: Mevalonic dependent inhibition of transendothelial migration in chemotaxis of human peripheral blood neutrophils by pravastatin. Circ Res 1997 Dec, 81(6): 963–969.PubMedGoogle Scholar
  40. 40.
    Zhou J, Chew M, Rabn HB, Falk E: Plaque pathology and coronary thrombosis in the pathogenesis of acute coronary syndromes. Scand J Clin Lab Invest Suppl 1999, 230: 3–11.PubMedCrossRefGoogle Scholar
  41. 41.
    Fitzsimmons C, Proudfoot D, Bowyer DE: Monocyte prostaglandins inhibit procollagen secretion by human vascular smooth muscle cells: implications for plaque stability. Atherosclerosis 1999 Feb, 142(2): 287–293.PubMedCrossRefGoogle Scholar
  42. 42.
    Soma MR, Donetti E, Parolini C: HMG CoA reductase inhibitors: in vivo effects on carotid intimal thickening in normal cholesterolemic rabbits. Arterioscler Thromb 1993, 13: 571–578.PubMedGoogle Scholar
  43. 43.
    Corsini A, Raiteri M, Soma M, Fumagalli R, Paoletti R. Simvastatin but not pravastatin inhibits the proliferation of rat aorta myocytes. Pharm Res 1991, 23: 173–80.CrossRefGoogle Scholar
  44. 44.
    Pollman MJ, Naumovski L, Gibbons GH: Vascular cell apoptosis: cell type-specific modulation by transforming growth factor-betal in endothelial cells versus smooth muscle cells. Circulation 1999, 99(15): 2019–2026.PubMedGoogle Scholar
  45. 45.
    Riessen R, Axel BI, Fenchel M, et al.: Effect of HMG CoA reductase inhibitors on extracellular matrix expression in human vascular smooth muscle cells. Basic Res Cardiol 1999 Oct, 94(5): 322–332.PubMedCrossRefGoogle Scholar
  46. 46.
    Laufs U, Marra B, Node K, et al.: 3-hydroxy-3-methylgluteryl CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing the rhoGTPase-induced down-regulation of p27 (IP1). Google Scholar
  47. 47.
    Newman TD, Hulley SB: Carcinogenicity of lipid-lowering drugs. JAMA 1996 Jan 3, 275(1): 55–60.PubMedCrossRefGoogle Scholar
  48. 48.
    Soma MR, Baetta R, DeRenzis MR, et al.: In vivo enhanced anti-tumor activity of carmustine by simvastatin. Cancer Res 1995, 55: 597–602.PubMedGoogle Scholar
  49. 49.
    Melichar D, Ferrandina G, Berschraegen CF, et al.: Growth inhibitory effects of aromatic fatty acids on ovarian tumor cell lines. Clin Cancer Res 1998, 4: 3069–3076.PubMedGoogle Scholar
  50. 50.
    Dimitroulakos J, Nohynek D, Backway KL, et al.: Increased sensitivity of acute myeloid leukemia to lovastatin-induced apoptosis. Blood 1999: 93: 1308–1318.PubMedGoogle Scholar
  51. 51.
    Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere TA, Langendorfer A, Stein EA, Kruyer W, Gotto AM. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of the AFCAPS/TEXCAPS. JAMA 1998, 279: 1615.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2000

Authors and Affiliations

  • John A. Farmer
    • 1
  1. 1.Department of MedicineBaylor College of MedicineHoustonUSA

Personalised recommendations